Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

Although farnesyltransferase inhibitors have shown promising activity in relapsed lymphoma and sporadic activity in acute myelogenous leukemia, their mechanism of cytotoxicity is incompletely understood, making development of predictive biomarkers difficult. In the present study, we examined the act...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ding, Husheng, McDonald, Jennifer S., Yun, Seongseok, Schneider, Paula A., Peterson, Kevin L., Flatten, Karen S., Loegering, David A., Oberg, Ann L., Riska, Shaun M., Huang, Shengbing, Sinicrope, Frank A., Adjei, Alex A., Karp, Judith E., Meng, X. Wei, Kaufmann, Scott H.
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2014
Teme:
Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007940/
https://ncbi.nlm.nih.gov/pubmed/23996484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.087734
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items